361 Capital’s Castle Biosciences CSTL Stock Holding History

361 Capital’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-24,581	Closed	-$733K	–	323
2020 Q1	$733K	Buy	+24,581	New	+$742K	0.33%	135

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

361 Capital's CSTL Position: Q2 2020 in Review

361 Capital sold out of Castle Biosciences (CSTL) in Q2 2020, closing a stake of 24,581 shares — an estimated $733K sold.

361 Capital first reported a position in CSTL in Q1 2020 and held it in 1 quarter. The position peaked at $733K in Q1 2020. 126 funds tracked by Wall St. Rank hold CSTL as of Q2 2020.

361 Capital reported no remaining Castle Biosciences position as of Q2 2020 after selling out during the quarter.
361 Capital sold 24,581 Castle Biosciences shares in Q2 2020, an estimated $733K.
361 Capital first reported a position in Castle Biosciences in Q1 2020 and held it in 1 quarter.
361 Capital's Castle Biosciences position peaked at $733K in Q1 2020.
126 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.